G1 Therapeutics Inc. (NASDAQ:GTHX) saw an upside of 1.68% to close Friday at $1.82 after adding $0.03 on the day. The 5-day average trading volume is 769,320 shares of the company’s common stock. It has gained $1.9700 in the past week and touched a new high 1 time within the past 5 days. An average of 1,382,465 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,025,672.
GTHX’s 1-month performance is -25.10% or -$0.7200 on its low of $1.7691 reached on 08/17/23. The company’s shares have touched a 52-week low of $1.77 and high of $17.49, with the stock’s rally to the 52-week high happening on 02/02/23. YTD, GTHX has lost -66.48% or -$3.6100 and has reached a new high 10 times. However, the current price is down -89.59% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
GTHX stock investors last saw insider trading activity on Aug 08.Velleca Mark A. (Director) most recently sold 60,000 shares at $2.00 per share on Aug 08. This transaction cost the insider $119,974. President and CEO, Bailey John E. (Jack) Jr., sold 2,719 shares at a price of $2.45 on Jul 05. Then, on Jul 05, Chief Operating Officer MURDOCK TERRY L sold 1,361 shares at a price of $2.45 per share. This transaction amounted to $3,339.
Valuation Metrics
GTHX stock has a beta of 1.88. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.04 while the price-to-book (PB) in the most recent quarter is 1.64.
G1 Therapeutics Inc.’s quick ratio for the period ended June 29 was 3.70, with the current ratio over the same period at 4.10. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.89, while the total debt to equity was 0.89. In terms of profitability, the gross margin trailing 12 months is 94.40%. The trailing 12-month EBITDA margin is -264.42% while for the period ending June 29, G1 Therapeutics Inc.’s operating margin was -74.70%. The firm’s gross profit as reported stood at $47.55 million against revenue of $51.3 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 552.93% to $8.71 million, while revenue of -$27.6 million was 416.88% off the previous quarter. Analysts expected GTHX to announce -$0.22 per share in earnings in its latest quarter, but it posted $0.14, representing a 163.60% surprise. EBITDA for the quarter stood at more than $11.95 million. GTHX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 90.34 million, with total debt at $55.93 million. Shareholders hold equity totaling $51.75 million.
Let’s look briefly at G1 Therapeutics Inc. (GTHX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 23.64% to suggest the stock is trending oversold, with historical volatility in this time period at 28.58%.
The stock’s 5-day moving average is $1.8360, reflecting a -7.14% or -$0.1400 change from its current price. GTHX is currently trading -25.10% above its 20-day SMA, -34.77% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -36.14% and SMA200 by-82.93%.
Stochastic %K and %D was 4.25% and 4.63% and the average true range (ATR) pointed at 0.1047. The RSI (14) points at 26.77%, while the 14-day stochastic is at 8.20% with the period’s ATR at 0.1120. The stock’s 9-day MACD Oscillator is pointing at -0.1133 and -0.2005 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for G1 Therapeutics Inc. (NASDAQ: GTHX), JP Morgan upgraded it to a Neutral rating. They previously had an Underweight rating on the stock.
